Vivimed Labs Limited – NSE:VIVIMEDLAB.NS

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.